124 results have been found
July 4, 2019
Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
June 27, 2019
Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2018
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?